Thu, Sep 18, 2014, 4:14 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Stryker Corporation Message Board

petersinger68 11 posts  |  Last Activity: Feb 14, 2011 11:15 AM Member since: Feb 7, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • petersinger68 by petersinger68 Feb 14, 2011 11:15 AM Flag

    Click on the link to get the latest EasyMed press release:


    http://www.easymedmobile.com/corporate/news.html

  • petersinger68 by petersinger68 Feb 8, 2011 10:31 AM Flag

    Medifocus MFS.V looks to have some real potential as it looks to begin phase III trials.

    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 8, 2011 10:20 AM Flag

    -Currently entering Phase III trial in a very large disease category
    Take a look at Medifocus MFS.V It seems to have some real potential with it entering Phase III trials.


    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 8, 2011 10:18 AM Flag

    Take a look at Medifocus MFS.V. It seems to have great potential


    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 8, 2011 9:54 AM Flag

    Check out Medifocus, MFS.V, it seems like it could make a big move soon with all the news coming out.


    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 7, 2011 2:04 PM Flag

    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 7, 2011 2:00 PM Flag

    Take a look at Medifocus. Great, experienced management that founded Celsion (CLSN).

    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • What do you all think about Medifocus, a company started by the founders of Celsion?


    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 7, 2011 11:26 AM Flag

    http://198.180.34.16/update.aspx?id=a5571



    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposible probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 7, 2011 9:46 AM Flag

    Take a look at this great opportunity.


    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposible probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 7, 2011 9:43 AM Flag

    Great opportunity!

    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposible probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

SYK
84.07+0.13(+0.15%)4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.